The principle of acalabrutinib in treating tumors

Acalabrutinib (Acalabrutinib) is a highly selective inhibitor of brutinib (BTK), mainly used to treat hematological malignancies such as B cell lymphoma. Its principle of treating tumors involves targeted intervention in the signaling pathways of BB cells.

BCell signaling pathway is a key biological pathway responsible for regulating the activation, proliferation and survival ofB cells. In some cancers, especially B cell-derived lymphomas and leukemias, this signaling pathway is abnormally activated, leading to abnormal proliferation and survival of malignant tumor cells. BTK is a key enzyme in the B cell signaling pathway, and its activity is closely related to the growth and survival of cancer cells.

Acotinib inhibits BTK and blocks key steps in the B cell signaling pathway, thereby exerting an inhibitory effect on malignant tumor cells. Specifically, acotinib binds to BTK and prevents its activation, thereby hindering the activation of downstream signaling molecules. This blocking process interrupts the survival and proliferation signals of cancer cells, prompting them to enter the apoptosis (cell death) pathway, thereby inhibiting tumor growth.

Compared with traditional chemotherapy drugs, the advantage of acotinib is that it is highly selective, more accurately interferes with abnormally active signaling pathways, and reduces adverse effects on normal cells. This also explains why therapeutic strategies targeting B cell signaling pathways, such as BTK inhibitors, have become effective means of treating specific hematological malignancies.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.